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We report the case of a congenital myasthenic syndrome due to a mutation in AGRN, the gene encoding agrin, an extracellular matrix
molecule released by the nerve and critical for formation of the neuromuscular junction. Gene analysis identiﬁed a homozygous
missense mutation, c.5125G>C, leading to the p.Gly1709Arg variant. The muscle-biopsy specimen showed a major disorganization
of the neuromuscular junction, including changes in the nerve-terminal cytoskeleton and fragmentation of the synaptic gutters. Exper-
iments performed in nonmuscle cells or in cultured C2C12 myotubes and using recombinant mini-agrin for the mutated and the wild-
type forms showed that the mutated form did not impair the activation of MuSK or change the total number of induced acetylcholine
receptor aggregates. A solid-phase assay using the dystrophin glycoprotein complex showed that themutation did not affect the binding
of agrin to a-dystroglycan. Injection of wild-type or mutated agrin into rat soleus muscle induced the formation of nonsynaptic acetyl-
choline receptor clusters, but the mutant protein speciﬁcally destabilized the endogenous neuromuscular junctions. Importantly, the
changes observed in rat muscle injected with mutant agrin recapitulated the pre- and post-synaptic modiﬁcations observed in the
patient. These results indicate that the mutation does not interfere with the ability of agrin to induce postsynaptic structures but
that it dramatically perturbs the maintenance of the neuromuscular junction.Introduction
Congenitalmyasthenic syndromes (CMS [MIM608931]) are
a heterogeneous group of disorders caused by genetic defects
affectingneuromuscular transmissionand leading tomuscle
weakness accentuatedbyexertion.CMSsare classiﬁedonthe
basis of their pathophysiology into presynaptic compart-
ment, synapticbasal lamina, andpostsynapticcompartment
CMSs. So far, 11 disease-causing genes coding for proteins
that have a key role at the neuromuscular junction (NMJ)
have been identiﬁed: CHAT (MIM 118490), CHRNA1 (MIM
100690), CHRNB1 (MIM 100710), CHRND (MIM 100720),
CHRNE (MIM 100725), COLQ (MIM 603033), RAPSN (MIM
601592), SCN4A (MIM 603967), MUSK (MIM 601296),
DOK7 (MIM 610285), and LAMB2 (MIM 150325).1–4 How-
ever, for half of CMS patients, the genes underlying the
disease have not yet been identiﬁed. Until now, the identi-
ﬁed genes encode for membrane receptors, ion channels,
enzymes, or structural proteins, but none has been found
to code for a secreted neural factor. Besides the mutations
recently described in the laminin b2 chain,4 the latest muta-The Amertions causing a CMS were identiﬁed in MUSK and DOK7,
genes encoding, respectively, the postsynaptic tyrosine
kinase receptor MuSK and Dok-7, a protein interacting
with the juxtamembrane intracellular domain of MuSK.5,6
DuringNMJdevelopment,MuSKplaysa central role in the
organizationof thepostsynaptic scaffold.MuSKactivation is
required to recruit downstream signaling components7,8,
which triggers the local aggregation and synthesis of post-
synaptic acetylcholine receptors (AChRs) and several other
postsynaptic proteins, such as the cytoskeletal protein rap-
syn.9,10 MuSK is activated by neural agrin, which is released
from motor neurons, and binds and activates the LRP4-
MuSK complex.7,8 Around embryonic day (E) 14 in mice
(corresponding to the 7th week of gestation in humans),
motor nerve terminals reach primary myotubes and secrete
both acetylcholine and neural agrin, which participate in
the stabilization of synaptic AChR clusters and the dispersal
of the aneural AChR clusters, respectively.11,12 Agrin is crit-
ical for synaptic differentiation because agrin-deﬁcient
mice die at birth from respiratory failure due to aberrant
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Agrin is a heparan sulfate proteoglycan that has been
shown to bind to laminins via its amino-terminal do-
main14 and to interact via its carboxy-terminal part with
LRP4 and a-dystroglycan.7,8,15 Agrin is encoded by AGRN
(MIM 103320), located on chromosome 1p36.33. The
complete cDNA is 7319 bp long (NM_198576) and
comprises 36 exons. The carboxy-terminal end of agrin
contains three laminin G-like (LG) domains, two of which
are required for binding to a-dystroglycan.16 Agrin mRNA
undergoes cell-speciﬁc alternative splicing at several sites.
Importantly, the two sites found in the carboxy-terminal
part of the protein, called A and B in chickens17 or y and
z in all mammals, including humans18, contain amino
acid inserts when synthesized by motor neurons but lack
these when synthesized in non-neural cells, including skel-
etal muscle ﬁbers.19 An amino acid insert at the B/z site of
agrin is required for MuSK activation and for NMJ forma-
tion.12,16 Consistent with the in vivo ﬁndings, the amino
acid insert renders agrin approximately 1000 times more
potent in inducing AChR clustering than the isoform
that lacks amino acid inserts.20
In this article, we report the case of a CMS patient
carrying a homozygous mutation in AGRN. Agrin recombi-
nant proteins, either normal or reproducing the mutation,
were produced and applied both in cell-culture systems
and by injection in vivo in rat soleus muscle. This allowed
us to evaluate the pathogenic consequences of this human
mutation by demonstrating its deleterious effect on NMJ
maintenance. These unexpected results imply that in-
ducing the formation of postsynaptic structures via agrin’s
N-terminal laminin-binding domain and C-terminal A/z
and B/z inserts is not the only function of agrin, which
also appears to play a crucial role in the maintenance of
the NMJs via other regions of the protein.
Material and Methods
Patient Mutation Analysis and Muscle Biopsy
Clinical evaluation, muscle biopsies, and blood samples were ob-
tained after informed written consent was secured in accordance
with the protocol approved by local ethics committees.
Mutation Analysis
Venous blood samples were drawn from the patients and their
unaffected relatives after obtaining their signed informed consent.
Genomic DNA was isolated using a blood DNA extraction kit
according to the manufacturer’s recommendations (Promega,
Mannheim, Germany). The 36 exons of AGRN and their ﬂanking
intronic regionswere ampliﬁedbyPCRand sequenced (see Table S1
online for primer sequences). PCR-ampliﬁed fragments were
puriﬁed, ﬂuorescently labeled with dideoxy terminators (BigDye
Terminator v3.1 Cycle Sequencing Kit, Applied Biosystems), and
run on an Applied Biosystems model 3730XL DNA Analyzer. The
GenBank reference numbers used for comparison of the mRNA
sequence of the AGRN exons is NM_198576.2. Any variant was
conﬁrmed as a disease-causing mutation by analysis of cosegrega-
tion in affected family members, conservation of the residue
among species and isoforms, and absence in at least 200 control156 The American Journal of Human Genetics 85, 155–167, Augustchromosomesofhealthyadults. Extensive sequencing forAGRN re-
vealed frequent variants that were thus considered to be polymor-
phisms (see Table S2 for missense polymorphisms).
Patient Muscle Biopsy
Amuscle biopsy specimenwas taken fromdeltoidmuscles by open
biopsy. The NMJ zone was determined by the small twitch
provoked by the tip of the scalpel on the surface of themuscle fasci-
cles. We conﬁrmed the presence of NMJs on a longitudinal strip of
the biopsy specimen by using the classic Koelle method21 to reveal
cholinesterase activity. ATPase staining of muscle ﬁbers was per-
formed on cryostat sections according to the method of Brooke
and Kaiser.22 Whole mounts of specimens ﬁxed with 4% parafor-
maldehyde were stained for AChR with FITC- or TRITC-labeled
a-bungarotoxin (Molecular Probes, Leiden, The Netherlands), and
for neuroﬁlaments with a 168 kDa neuroﬁlament antibody (2H3,
Hybridoma Bank, IA). The specimens were observed by confocal
microscopy (Carl Zeiss LSM510,Oberkochen, Germany). Fragmen-
tationof theNMJswas calculated as indicated below for injected rat
muscle; see also Figure S1.
In addition, part of the biopsy specimen was processed for
immunocytochemical analysis of cryostat sections with TRITC-
labeled a-bungarotoxin and with polyclonal antibodies raised
against agrin andMuSK provided by one of us (M.R.). The sections
were observed by ﬂuorescence microscopy (Zeiss Axiophot, Ober-
kochen, Germany). Electron microscopy of NMJs was performed
by conventional methods.
Experimental Expression of Mutated Agrin
Production of Wild-Type and Mutated Agrin Recombinant Proteins
Because coding sequences for chicken and human agrin are highly
homologous, we used a construct coding for a chicken mini-agrin.
The chicken mini-agrin was cloned into the pCEP-Pu expression
vector and codes for the amino-terminal NtA region followed by
one follistatin-like repeat (25 kDa in size), which was then fused in-
frame with the carboxy-terminal part (95 kDa size) of chicken
agrin.23 The recombinant protein was targeted to the secretory
pathway by the signal peptide of BM40, and it included a carboxy-
terminal His6 tag. The carboxy-terminus included the 4- and 8-
amino-acid inserts at the A/y and B/z sites and thus represents the
neural isoform. Site-directed mutagenesis was performed by Gene-
cust (Evry, France) and yielded a construct containing the same
c.5127G>Cmutation as that identiﬁed in the patient. Recombinant
wild-type and mutated chicken mini-agrins were puriﬁed from
conditioned media of 293 EBNA cells stably transfected with pCEP-
Pu/wild-type ormutatedmini-agrin plasmids. Proteinswere puriﬁed
from culturemediumwith a Ni-column (Ni-NTA agarose, QIAGEN).
Administration of Agrin Recombinant Proteins in Myogenic Cells
in Culture
C2C12 cells seeded at a density of 5 3 104 cells per 35 mm dish
were cultured for 24 hr at 37C and 5% CO2 in a proliferation Dul-
becco’s modiﬁed Eagle’s medium (DMEM) supplemented with
antibiotics and 20% fetal bovine serum. They were switched to
a differentiation DMEM containing 5% horse serum and antibi-
otics and cultured for 4 days at 37C and 5% CO2. After 4 days,
wild-type or mutant agrin was added at different concentrations
(three dishes per concentration) for 18 hr at 37C. Cells were
washed twice with pre-warmed PBS, ﬁxed for 10 min in PBS con-
taining 4% paraformaldehyde (PFA), and then washed three times
in PBS containing 0.1 M glycine. They were then incubated in PBS
containing 3% BSA (PBS-BSA) for 2 hr followed by an incubation14, 2009
with TRITC-aBGT (1/500, Molecular Probes) in PBS-BSA for 1 hr.
After several washes, plates weremounted in Vectashieldmounting
medium (Abcys, Paris, France) and observed with a 403 objective
lens under an Olympus IX70 inverted microscope (Olympus
Europa, Hamburg) linked to a CDD camera (Princeton Cool
SNAP Fx, Trenton, NJ). Ten ﬁelds per dish were analyzed. AChR
cluster number and myotube area were obtained with ImageJ soft-
ware (NIH, Bethesda). The experiment was repeated twice.
For quantiﬁcation of surface AChR number, C2C12 myotubes
were ﬁxed in PBS-4%-paraformaldehyde for 10 min, rinsed in PBS,
incubated with 20 nM 3H-a-bungarotoxin in PBS-0.2%-BSA
(TRK603-50UC1, GE Healthcare) for 45 min at room temperature,
and washed four times in PBS-0.2%-BSA followed by PBS. Cells
were solubilized in 200 ml PBS-1%-SDS, and 800 ml of scintillation
liquid (UltimateGold,Packard)wasadded to thecell lysate. 3Hradio-
activity bound per culture dishwas determined in a b counter (1900
TR, Packard). All toxin data were corrected for nonspeciﬁc binding,
determined in the presence of ‘‘cold’’ 1 mM a-bungarotoxin (B-1601,
Invitrogen). As an internal control, the total protein content per
dish was measured. Protein concentration was determined with a
bicinchoninic acid protein assay (Pierce, Rockford, IL, USA).
Administration of Agrin Recombinant Proteins in 293T Cells Coexpress-
ing MuSK and LRP4
293T cells, transfected with LRP4 (kindly provided by Dr. Lin Mei)
and HA-tagged MuSK expression vectors (2 mg each) via Lipofect-
amine 2000 (Invitrogen), were switched to DMEM without serum
for 3 hr prior to stimulation with various concentrations of wild-
type or mutated agrin (0.1 to 5 nM) for 1 hr. Cells were rinsed
with ice-cold PBS and extracted in lysis buffer.24 Lysates were
pre-cleared by centrifugation and incubated with anti-HA anti-
body overnight. Antibody was captured with protein G-Sepharose
beads, which subsequently were washed four times in lysis buffer.
Bound proteins were eluted from the beads with SDS sample
buffer, resolved by SDS-PAGE, and transferred to Immobilon-P
membranes (Millipore). Membranes were blocked in Tris-buffered
saline (TBS) containing 5% skim milk and incubated with 4G10
antibody for anti-phosphotyrosine detection in TBS þ 3% skim
milk and with HA antibody for MuSK detection in TBS þ 1%
skim milk. Phosphorylation was estimated with ImageJ software.
Three different experiments were done in triplicate.
Affinity of Agrins for the Dystrophin-Associated Glycoprotein Complex
A solid-phase assay was used. Ninety-six-well plates were coated
overnight at 4C and stirred with 0.5 mg of protein (dystrophin-
associated glycoprotein complex [DGC] or BSA) in a pH 9.6,
50 mMNaHCO3 solution. The wells were then washed three times
for 5 min with 200 ml of buffer A (PBS, 0.05% Tween, 1 mMCaCl2,
and 1 mM MgCl2) and next incubated for 1 hr at room tempera-
ture with 200 ml of buffer B (PBS, 0.05% Tween, 1 mM CaCl2,
1 mM MgCl2, and 3% BSA). After three 5 min washes with 200 ml
of buffer A, the wells were incubated with serial dilutions of each
agrin in buffer B for 3 hr. After three 5 min washes in buffer A, the
wells were incubated for 60 min with 100 ml of a 1:30,000 dilution
of the agrin antibody in buffer B. The wells were then washed
three times for 5 min with 200 ml of buffer A and next incubated
for 45 min with 100 ml of HRP-conjugated anti-rabbit antibody
in buffer B. After three 5 min washes with 200 ml of buffer A,
100 ml of ABTS detection solution (Roche, Mannheim, Germany)
was added to the wells, and the optical density was read at 405 nm
after 20 min. The background value, given by the binding of agrin
to BSA, was subtracted from the results with DGC. DGC was
extracted from chicken muscle as previously described for the
initial studiesof the interactionsbetweenagrin anddystroglycan.25The AmerInjection of Agrin Recombinant Proteins in Rat Soleus Muscle
All experiments on rats were performed in accordance with
European Community guidelines for laboratory animal handling.
Four-week-old OFA female rats (Charles River Laboratories) were
anesthetized with 80 mg/kg ketamine and 15 mg/kg xylazin. Five
micrograms of either wild-type or mutated mini-agrin diluted in
80 ml of 0.9%NaClwere injected in the soleusmuscle in the vicinity
of the NMJ zone with a 1 ml syringe with a 27 gauge needle. Three
rats per experimental condition (i.e., vehicle alone, wild-type agrin,
andmutated agrin) were studied. Morphological analyses were per-
formed with confocal microscopy as described above for human
biopsy specimens. The area of synaptic gutters per NMJ and the
mean a-bungarotoxin ﬂuorescence intensity within that area were
measured with ImageJ software. We studied fragmentation of the
NMJsbycounting thenumberofwell-individualized synapticgutter
fragments composing one given NMJ and calculating the mean
number of fragments for all NMJs studied, as shown in Figure S1.
Results
Study of the Patient
Clinical Data
The indexpatient is a 42-year-oldwomanwhoreportshaving
been unable to run since early childhood and having had
right-lid ptosis ‘‘since forever,’’ this condition was corrected
surgically at the age of 22 years. Our examination showed
she had mild bilateral lid ptosis but that ocular pursuit and
pupillary reactivity were normal. There was a mild facial
weakness but normal function of the axialmuscles. The glutei
and psoas muscles were slightly weak (MRC4þ/5), and the
patient had some difﬁculty walking on her heels. Atrophy,
scoliosis, and contractures were not found, but the thorax
and pelvis were thin. During the study of nerve conduction,
single stimuli elicited normal compound muscle action
potentials (CMAPs) and produced no ‘‘double’’ responses.
Repetitive stimulation at 3 Hz resulted in a clear decrement
of the CMAPs evoked from the trapezius (16%) and from the
tibialis anterior (29%)muscles (normal< 10%), but no poten-
tiation was seen after high-frequency repetitive nerve stimu-
lation at 30 Hz with recording over tibialis anterior and ﬁrst
interosseus dorsalismuscles. By needle electromyography, no
abnormal potentials were seen at rest in the deltoid or tibialis
anterior muscles, but during 20 voluntary contractions the
interference pattern analysis ratio was found to be abnormal
(1.48, normal< 1), indicative of an early recruitment of poly-
phasicmotor-unitpotentials, a commonresult inmyasthenic
syndromes as well as in mild myopathies. Cholinesterase
inhibitors and 3,4-diaminopyridine (3,4-DAP) were ineffec-
tive. The weakness ﬂuctuated; it worsened during menstrual
periods and during her pregnancy, but overall, the outcome
showednodeteriorationofmuscle function.Diplopia, bulbar
symptoms, and dyspnea were never reported.
The disease inheritance is autosomal recessive (Figure 1).
The patient was born to asymptomatic parents who came
from the same Swiss village. The patient’s grandparents
and great-grandparents were cousins. The index patient
has ﬁve siblings, among whom a 36-year-old brother also
presented CMS with similar manifestations: he has hadican Journal of Human Genetics 85, 155–167, August 14, 2009 157
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Figure 1. Identification of the Mutation c.5125G>C in AGRN exon 29 and Hereditary Transmission
(A) Sequence chromatograms from normal (wild-type) and affected (proband III-5) individuals are shown.
(B) Family pedigree. The proband is indicated by an arrow. The expected nucleotide change p.Gly1709Arg transmitted in this consan-
guineous family is indicated below the symbols. ND: not determined.difﬁculties in running since early childhood and had a ﬂuc-
tuating right ptosis (corrected at the age of 34 years),
normal ocular pursuit, and intermittent mild masticatory
difﬁculties with no dyspnea. The muscle examination
was normal, but he had a thin thorax and ﬂat feet. The
course of the disease had been stable. The edrophonium
test was negative, and pyridostigmine and ambenonium
were ineffective. 3,4-DAP was mildly beneﬁcial but was
not tolerated. An abnormal (10% to 14%) decrement was
found during repetitive stimulation at 3 Hz over orbicularis
oculi, trapezius, and tibialis anterior muscles. The other
family members were not examined.158 The American Journal of Human Genetics 85, 155–167, AugustEphedrine was recently given to the two patients. Im-
provement of the clinical symptoms after administration
of ephedrine (50 mg/day for 3 days and then 2 mg/kg
each morning) led to a remarkable and sustained increase
in muscle performance and endurance and improved
general well-being.
Mutation Analysis
All the known genes involved in CMS (CHAT, CHRNA1,
CHRNB1, CHRND, CHRNE, COLQ, RAPSN, SCN4A, MUSK,
and DOK7) with the exception of LAMB2 were initially
sequenced, and no mutations were found. As part of a
screen for candidate genes in CMS patients, a missense14, 2009
transversion, c.5125G>C, in exon 29 of AGRN was identi-
ﬁed in the family, and this transversion led to the substitu-
tion of a conserved hydrophobic glycine for the basic
amino acid arginine in the C-terminal, laminin G-like 2
domain of agrin (p.Gly1709Arg; RefSeq: NM_198576.2).
The index patient III-5 was homozygous for the amino
acid change (Figure 1). Molecular testing of the family
members conﬁrmed the recessive inheritance of the substi-
tution. Because the father of the proband (II-3) was
deceased, his brother (II-5) and sister (II-7) were tested:
his sister is heterozygous for the mutant allele, indicating
that one mutant allele came from the father. The other
allele came from the mother because she carries a single
mutant allele. The affected brother (III-4) of the index
patient harbors the same homozygous mutation, and the
unaffected siblings harbor one mutant allele (III-1, III-2)
or none (III-3). The identiﬁcation of this ﬁrst pathogenic
amino acid substitution in AGRN indicates that a founder
effect in this village is probable and that the parents of
the proband are also consanguineous. The p.Gly1709Arg
substitution was not detected in 200 normal alleles.
Morphological Analysis of Patient Muscle-Biopsy Specimen
ATPase activity staining on cryostat sections showed type I
ﬁber predominance and type II ﬁber atrophy in which
a few ﬁber grouping islets were compatible with denerva-
tion-reinnervation processes (not shown). Whole-mount
observations revealed that the global architecture of
NMJs was perturbed in the patient. Whereas whole-mount
preparations from normal individuals showed a typical
fork-shaped nerve terminal innervating a well-deﬁned
synaptic structure, the patient muscle-biopsy specimen
presented pre- and postsynaptic alterations. Among the
21 NMJs observed in the biopsy specimen from the
patient, only 1 had a normal shape (normal), nine showed
fragmented and dispersed synaptic gutters with evanes-
cent borders and absence of nerve terminal proﬁles that
are characteristic of denervation (denervated), seven
NMJs were in a process of remodeling with either partially
denervated or reinnervating proﬁles (remodeling), and
four showed very thin axons contacting small newly
formed synaptic cups (neoformed) (Figure 2A; for a repre-
sentation in percentage, see Figure 2B). Of particular
interest, within the group of NMJs undergoing remodel-
ing, the morphology of the ramiﬁcations of the nerve
terminals was abnormal: the neuroﬁlaments in the axon
terminal had a disheveled appearance (Figure 2A; see insert
of the NMJ in remodeling), whereas at control NMJs the
axon terminal was more compact and therefore thinner
(Figure 2A, see insert of the normal NMJ). Another striking
feature of the NMJs of the patient was the fragmentation of
the synaptic gutters into several discontinued postsynaptic
gutters as quantiﬁed in Figure 2C (see also the Material and
Methods and Figure S1). The partial denervation and rein-
nervation patterns seen in the confocal microscope was
also observed by electron microscopy (Figure 3). In the
selected NMJs, the morphology of the postsynaptic appa-
ratus showed only slight abnormalities and enlarged sub-The Amerneural folds. Conversely, the presynaptic compartment
was perturbed and showed either a complete absence of
axon proﬁles and the replacement by Schwann cell
processes (denervated NMJ) or a partial reinnervation (in
remodeling) characterized by small axon terminals that
contained normal amounts of synaptic vesicles and some
‘‘dense’’ myelin ﬁgures but that occupied only part of the
A
Normal               Denervated
Remodeling Neoformed
B C
ag
m
en
ts
 p
er
 N
M
JNormal
Denervated
Remodeling
Neoformed
60
80
100
3
4
5
6
N
um
be
r 
of
 fr
P
er
ce
nt
ag
e 
of
 to
ta
l n
um
be
r 
of
 N
M
Js
 
Patient Control   Patient
0
20
40
0
1
2
Figure 2. Abnormal NMJs Observed in Patient Muscle-Biopsy
Specimen
(A) Whole-mount preparations stained for AChR with a-bungaro-
toxin in red and stained for axon terminals with neuroﬁlament
antibody in green. The different types of NMJs can be classiﬁed
into four categories: normal, denervated, remodeling, and neo-
formed. The axonal branch classically ends as a fork and inner-
vates a well-deﬁned synaptic structure (normal). No axon proﬁle
faces the fragmented postsynaptic compartment (denervated). A
thin axon terminal reinnervates some but not all of the frag-
mented gutters of the NMJ (remodeling). A thin axon innervating
newly formed small and simpliﬁed NMJs can be observed (neo-
formed). In the bottom insert, note the disheveled appearance of
the neuroﬁlament staining observed in the NMJ in remodeling.
The scale bar represents 10 mm for the four low-magniﬁcation
prints and 4 mm for the two inserts.
(B) The graph represents the classiﬁcation of the NMJs observed
in the patient muscle-biopsy specimen into four categories
(expressed as a percentage of the 21 NMJs examined).
(C) The fragmentation of NMJs was signiﬁcantly increased in the
patient in comparison with control muscle biopsies, according
to the Mann-Whitney test (control: n ¼ 28; patient: n ¼ 21;
U ¼ 48,500, p < 0.001). Colored squares represent medians, and
boxes represent 25th to 75th percentiles.ican Journal of Human Genetics 85, 155–167, August 14, 2009 159
postsynaptic compartment. Terminal Schwann cells en-
cased the axon terminals but never invaded the synaptic
cleft, at least in the NMJs examined, contrary to what
can be observed in other types of CMSs.4,26
To test whether the mutation in AGRN would affect
expression of the protein, we next stained transverse cryo-
stat sections with agrin and MuSK antibodies. As shown in
Figure 4, both agrin and MuSK accumulated at the NMJs,
and their expression levels were not different from those
of controls. Altogether, these results indicate that agrin
and its downstream targets are expressed and localized
correctly in the patient’s muscle but that perturbation of
the overall NMJ organization has a marked effect on the
presynaptic compartment.
Functional Evaluation of the Agrin Mutation
To investigate how the mutation would affect the NMJ as
seen in the myasthenic syndrome observed in the patient,
we producedmutated andwild-type recombinant agrin. To
this end, we used a chickmini-agrin construct that encodes
a fusion protein between a 25 kDa fragment of the amino-
terminal end and a 95-kDa fragment of the carboxy-
terminal end (Figure 5). The construct included the appro-
priate amino acid inserts at the A/y and B/z sites and thus
A
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Figure 3. Electron Micrographs of Two NMJs from the Patient
Biopsy Specimen
(A) An emptied NMJ is fully engulfed by a terminal Schwann cell
(S) whose nucleus is clearly visible (N).
(B) A small reinnervating axon terminal (A) partially encased by
Schwann cell processes (S) intrudes into the synaptic cleft, and
there is pronounced reduction of the area of apposition between
the axon terminal (A) and the postsynaptic membrane. The scale
bar represents 2 mm in both prints.160 The American Journal of Human Genetics 85, 155–167, Augustencoded the neural form of agrin. Human and chick
agrin are highly homologous and, most importantly, the
Gly1709 residue of human agrin is conserved in chicks.
Moreover, the chick mini-agrin allows the production of
recombinant agrin23 and has been shown to be sufﬁcient
to substitute for agrin in other species and to rescue the
phenotype in agrin knockout mice.12,27 We performed
site-directed mutagenesis to reproduce the p.Gly1709Arg
mutation of the patient. Wild-type and mutant recombi-
nant agrin proteins were produced in 293-EBNA cells and
puriﬁed as described in the Material and Methods section.
For simpliﬁcation, instead of ‘‘neural form of mini-agrin,’’
the word ‘‘agrin’’ will be used in the following sections.
A
B
Figure 4. Cross-Sections of the Patient Biopsy Specimen Were
Double Labeled for AChR in Red and for Agrin or MuSK in Green
Both agrin (A) andMuSK (B) colocalize with AChR at the NMJ, and
their relative expression between the control and patient appears
roughly similar. The scale bar represents 20 mm and applies to
the eight prints.14, 2009
Figure 5. Protein Domains of the Recombinant Mini-Agrin and Localization of the p.Gly1709Arg Substitution
The neural mini-agrin is deleted from its central region. It contains the SS-NtA domain at the N-terminal region and the A/y and B/z
inserts at the C-terminal region. The p.Gly1709Arg substitution is located in the laminin G-like 2 domain (LG2) in the region of agrin
interaction with a-dystroglycan, heparin, and integrins.The Mutation in Agrin Does Not Alter AChR Clustering in
Cultured Myotubes
To test whether the mutation would affect the AChR-
aggregating activity of agrin, we used C2C12 myotubes
in culture. C2C12 myotubes express agrin but only the
form that lacks inserts at the y and z sites. This form of
agrin does not contribute to AChR clustering induced by
the addition of agrin.28 C2C12 myotubes were cultured
with wild-type or mutant neural agrin for 18 hr at different
concentrations. AChR clusters were then visualized with
ﬂuorescent a-bungarotoxin, and the number of clusters
of more than 5 mm in length were counted (Figure 6). No
difference in clustering activity between wild-type and
mutant agrin was noted with close dose-response curves
and an EC50 (effective concentration needed to induce
a half-maximal response) of about 0.05 nM. To check
whether the mutation would affect the expression of
AChR, we quantiﬁed surface and total AChRs by using
3H-a-bungarotoxin. The results indicated that, in our
experimental conditions, wild-type and mutant agrin
affected neither the total amount of AChR nor its recruit-
ment to themembrane (data not shown). Altogether, these
results suggest that the mutation does not signiﬁcantly
impair the AChR clustering function of agrin.
The Mutation in Agrin Does Not Alter MuSK Phosphorylation
in Nonmuscle Cells Expressing Both LRP4 and MuSK
To determine whether the mutation affects the capacity of
agrin to activate MuSK, 293T cells were cotransfected with
both LRP4 and MuSK expression vectors. Because LRP4 is
the agrin receptor, it confers to agrin the ability to phos-
phorylate MuSK in non-muscle cells.7 MuSK phosphoryla-
tion was evaluated in the presence of wild-type or mutated
agrin at different doses ranging from 0.1 to 5 nM. As
shown in Figure 7, the mutation does not inhibit the
ability of agrin to activate MuSK.The AmerThe Mutation in Agrin Does Not Affect Its Binding
to a-dystroglycan
Since the mutation is located in the region of agrin respon-
sible for interactions with a-dystroglycan,16 the impact of
the mutation on the afﬁnity of agrin for puriﬁed DGC
Figure 6. Effects of the Mutated Agrin on AChR Aggregation
Dose-response curves for AChR-aggregating activity of wild-type
or mutant agrins. C2C12 myotubes were incubated for 18 hr
with recombinant agrins at the concentrations indicated, and
the number of AChR clusters per myotube was determined as
described in the Material andMethods. Each data point represents
results (mean 5 SD) from triplicate myotube cultures; ten ﬁelds
were studied per dish. Data shown represent the results of one
representative experiment. The number of AChR clusters without
agrin and the half-maximal and maximal number of clusters are
indicated by dotted lines.ican Journal of Human Genetics 85, 155–167, August 14, 2009 161
was evaluated in a solid phase assay (ELISA; Figure 8). The
results showed that the mutation did not diminish the
binding of agrin to DGC.
Altogether, our results show that the mutation does not
affect agrin’s ability to activate MuSK and to cluster AChRs,
nor does it affect the interaction with a-dystroglycan.
Effects of Mutated Agrin in Rat Soleus Muscle
To address in vivo the consequences of the mutation, we
injected recombinant wild-type and mutant agrin proteins
into rat soleus muscle to evaluate the formation of extrasy-
naptic AChR clusters and possible NMJ remodeling. Mus-
cles were collected two weeks after injection, and whole
muscles or cryostat sections were labeled for AChRs with
a-bungarotoxin and labeled for agrin, MuSK, or neuroﬁla-
ment with the appropriate antibodies. As expected, agrin
injection induced the formation of extrasynaptic AChR
clusters that were never contacted by nerve endings,
even when they were located in the vicinity of the synaptic
zone (Figure 9A). When species-speciﬁc chick agrin anti-
bodies were used for detection of injected chick agrin, we
found that the extrasynaptic AChR clusters were associated
with accumulation of chick agrin. Consistently, MuSK also
A
B
Figure 7. Effects of the Mutated Agrin on MuSK Phosphoryla-
tion
293T cells expressing both MuSK and LRP4 were incubated with
wild-type and mutant agrin at different concentrations (0.1–
5 nM). A representative experiment is shown with 0.1 and 1 nM
agrin.
(A) HA-MuSK was immunoprecipitated (IP) with an anti-HA anti-
body (HA), and immunoblots (IB) for MuSK (HA) and phosphory-
lated MuSK (pTyr) were performed.
(B) Phosphorylation, estimated with ImageJ software, is expressed
as n-fold activation. No signiﬁcant differences between wild-type
or mutant agrin were observed at any concentration studied.162 The American Journal of Human Genetics 85, 155–167, Augustaccumulated at these sites (Figure S2). No obvious differ-
ence in the number, size, or shape of ectopic AChR clusters
could be seen between muscles injected with mutant and
wild-type agrin, indicating that AChR-inducing activity
of agrin at these extrasynaptic sites was not signiﬁcantly
altered by the p.Gly1709Arg substitution. Thus, the
in vivo paradigm of inducing extrasynaptic AChR aggre-
gates was quite similar to what was observed for AChR clus-
ters on cultured C2C12 myotubes.
When we tested deposition of recombinant chick agrin
at the endogenous NMJs, we observed that they were efﬁ-
ciently incorporated at the NMJ sites (Figure 9B). The stain-
ing was speciﬁc; it could not be detected upon saline injec-
tion. This accumulation of agrin is not directly correlated
with the amount of protein injected, thus precluding the
possibility of performing dose-response experiments. The
amounts of agrin protein in the basement membrane of
transgenicmice expressing small amounts of the transgene
are still similar to those of mice that express much higher
levels of the transgenic mRNA.29
The morphology of the pre- and postsynaptic compart-
ments was evaluated in injected muscles by AChR and
neuroﬁlament staining (Figure 10A). First, the total area
of the synaptic gutters of each NMJ was measured on ‘‘en
face’’ views, and the mean ﬂuorescent intensity of the
a-bungarotoxin staining was measured. The presence of
mutant agrin did not signiﬁcantly alter the area of the
primary gutters (mutant agrin ¼ 95% 5 9%; wild-type
agrin ¼ 97% 5 8% of area in saline-injected control
Figure 8. Evaluation of Agrin Binding to DGC in Solid-Phase
Assay
Various amounts of wild-type and mutant agrin were added to
0.5 mg of DGC bound to 96-well plates. The amount of soluble
agrin added is indicated in micrograms on the abscissa. The
amount of bound agrin is expressed as absorbance 5 SD.14, 2009
animals) or the mean intensity of AChR staining per NMJ
(mutant agrin ¼ 97% 5 13%; wild-type agrin ¼ 101% 5
12% of mean intensity per NMJ in saline-injected control
A
B
Figure 9. Chick Agrin Colocalizes with Extrasynaptic AChR Clus-
ters and Endogenous NMJs in Both Wild-Type and Mutated
Agrin-Injected Muscle
(A) Agrin-induced extrasynaptic clusters are double labeled for
AChR in red and for chick agrin in green and observed by confocal
microscopy. The calibration bar represents 4 mm.
(B) Native NMJs are double labeled for AChR in red and for chick
agrin in green and observed by confocal microscopy. The calibra-
tion bar represents 10 mm. Note that chick agrin is present at NMJs
in both wild-type and mutated-agrin-injected muscle, but not in
saline-injected rat soleus muscle.The Amerianimals), consistent with the observation in cultured
myotubes that the mutation does not affect AChR expres-
sion and recruitment to themembrane. NMJmorphologies
were next classiﬁed according to the categorization used
for human biopsies (see Figure 2A): (1) fork-shaped nerve
terminal innervating a well-deﬁned synaptic structure
(normal); (2) absence of nerve terminal with fragmented
AChR organization (denervated); (3) modiﬁed nerve termi-
nals with fragmented AChR gutters corresponding to a re-
modeling process of either denervation or reinnervation
(remodeling); and (4) newly formed NMJs (neoformed)
with large-diameter axons associated with small AChR
cups or gutters.
Figure 10B shows the distribution of NMJs from the
various injected muscles into these four categories. Saline-
injected muscles mostly presented normal-shaped NMJs,
with 5% remodeling and barely any denervated or neo-
formed NMJs. In muscles injected with wild-type agrin,
60% of the NMJs were normal, but 40% showed some re-
modeling, which was signiﬁcantly higher than in controls.
Denervated or neoformed NMJs were almost never seen.
Conversely, in muscles injected with mutant agrin, only
4% of the NMJs were normal, 44% underwent remodeling,
34% were completely denervated, and 18% were classiﬁed
as neoformed.
When the presynaptic compartment of the ‘‘remodel-
ing’’ NMJs was analyzed more closely, major variations in
the caliber and structure of the nerve terminals were
observed. Peculiar aspects of the disassembly of terminal
axons included a disheveled appearance of the stained
neuroﬁlaments (see lower insert in Figure 10A) and were
observed in 70% of the remodeling NMJs after injection
of mutated agrin, very similar to what was observed in
the patient biopsy specimen, whereas such features were
never observed in the remodeling NMJs after injection of
wild-type agrin.
To further assess the changes observed on the postsyn-
aptic side, we evaluated NMJ fragmentation by counting
the number of individualized synaptic gutters (visualized
with ﬂuorescently labeled a-bungarotoxin) for each NMJ,
except for neoformed NMJs (Figure S1), as was done for
the patient muscle-biopsy specimen. Whereas normal
NMJs are made of a single continuous gutter, denervated
and remodeling NMJs comprise several of them. In com-
parison to injection with wild-type agrin or saline, the
injection of mutant agrin induced a striking increase in
the mean number of synaptic gutter fragments in indi-
vidual NMJs (Figure 10C).
Altogether, these results demonstrate that the agrin
p.Gly1709Arg substitution perturbs the organization of
the NMJ, on both the pre- and postsynaptic sides, in a
manner highly reminiscent of what was observed in the
patient biopsies. Mutant agrin affects neither the size nor
the total amount of AChRs at the NMJ, thus demonstrating
that the perturbations induced by p.Gly1709Arg are not
associated with a signiﬁcant impairment of AChR expres-
sion at the postsynaptic membrane.can Journal of Human Genetics 85, 155–167, August 14, 2009 163
AB
C
Figure 10. Mutated Agrin Induces Remodeling of Pre-existing
NMJs and Their Fragmentation
(A) Rat soleus muscles were injected with saline, wild-type agrin,
or mutated agrin. After 2 weeks, muscles were removed and
stained for AChRs with a-bungarotoxin (red) and neuroﬁlament
antibodies (green). As for the patient biopsy specimen (see Fig-
ure 2), the different NMJs observed were divided into four cate-
gories: normal, denervated, remodeling, and neoformed. Note in
the bottom insert the disheveled appearance of the stained neuro-
ﬁlaments observed in the NMJ in remodeling. This peculiar aspect
of disassembly of terminal axons was speciﬁc of NMJs after injec-
tion of mutated agrin and was never observed after injection of
wild-type agrin. The scale bar represents 10 mm for the four low-
magniﬁcation prints and 4 mm for the two inserts.
(B) The graph represents the distribution of the NMJs in these four
categories depending on the injection: saline, wild-type agrin, or164 The American Journal of Human Genetics 85, 155–167, AugustDiscussion
We describe here a case of CMS associated with a homozy-
gous missense mutation c.5125G>C in AGRN, which
induces the expression of a functionally abnormal
p.Gly1709Argagrinprotein.TheCMS isof autosomal-reces-
sive inheritance and occurred in the context of an inbred
community. Both parents carry one mutated allele that
has been transmitted to their two affected children. Both
siblings present quite similar mild and stable symptoms
that began in childhood with lid ptosis without diplopia,
mild lower proximal limb weakness, and a thin thorax
andpelvis. Fluctuationswere reported, andabnormaldecre-
ment during repetitive nerve-stimulation studies was
present. Both patients are unresponsive to cholinesterase
inhibitors, and the index patient was unresponsive to
3,4-DAP, whereas her brother was slightly improved by
this treatment but did not tolerate it. Both patients’ condi-
tions were remarkably improved after ephedrine adminis-
tration. The three other children are asymptomatic. Among
them, two carry one mutated allele but were not examined
clinically or electrophysiologically.
NMJ alterations in the muscle-biopsy specimen of the
index patient suggested that they could be related to the
mutation. The injectionofmutant agrin in rat soleusmuscle
clearly perturbs the organization of NMJ pre- and postsyn-
aptic compartments. These perturbations are revealed by
the fragmentation of the synaptic gutters and thedisappear-
ance and/or restructuring of the nerve terminals. The
c.5125G>C mutation in AGRN is therefore sufﬁcient to
impair the NMJ, and the similarity of the features it induces
to those observed in themuscle biopsies of the patient indi-
cates that this mutation is indeed responsible for the CMS.
Interestingly, wild-type and mutant agrins have quite
similar effects on AChR aggregation when applied to
cultured muscle cells. In addition, in vivo, both mutated
and wild-type chick agrins efﬁciently induce the formation
of extrasynaptic AChR clusters in injected rat muscle, thus
demonstrating that they can trigger the formation and the
activity of the LRP4-MuSK complex.7,8 Likewise, wild-type
and mutant agrins have the same ability to activate and
phosphorylate MuSK. Finally, AChR levels are unaffected
by the mutation, as evidenced by the absence of a decrease
in synaptic AChR density or primary gutter area. Alto-
gether, these observations indicate that the ability of
neural agrin to induce AChR clustering, MuSK phosphory-
lation, and AChR expression is not affected.
The main effect of the injected mutant agrin is on the
destabilization of pre-existing adult NMJs. The architecture
mutatedagrin.Note that thedistributionformutatedagrin is similar
to that observed in the patientmuscle-biopsy specimen (Figure 2B).
(C) The fragmentation of NMJs was signiﬁcantly increased in
mutated agrin-treated muscles in comparison with the saline-
treated and even the wild-type agrin-treated muscles according to
Kruskal-Wallis test (saline: n¼ 42; wild-type agrin: n¼ 45; mutated
agrin: n ¼ 44; H ¼ 52; p < 0.001). Colored squares represent
medians, and boxes represent 25th to 75th percentiles.14, 2009
of the NMJ is profoundly altered: synaptic gutters are
highly fragmented, and axon terminal branches are greatly
modiﬁed in comparison with muscles injected with wild-
type agrin or saline. In addition, numerous NMJs are
denervated, suggesting that their axon terminals have
lost their capacity to regenerate, contrary to what occurs
with the injection of wild-type agrin, when no denervated
NMJs are observed. The possibility that these changes
might be due to an immune response related to the expres-
sion of chick agrin in another species has already been
dealt with by others and ruled out.30 Moreover, the
protein-injection method used in this paper was also em-
ployed by others without triggering an immune re-
sponse.31–33 The NMJ changes observed experimentally
result from the injection of agrin doses above the physio-
logical levels. However, our immunoﬂuorescence images
show that the injected NMJs probably incorporate normal
amounts of agrin. This is consistent with previous work
showing that the NMJ regulates the amount of agrin it
incorporates, regardless of the expression level of the
protein.12,29 Because injected agrin is efﬁciently incorpo-
rated into the NMJs, it can compete with the endogenous
agrin, and given the high molecular excess of injected
agrin, it might replace most of the endogenous molecules.
Injected NMJs thus probablymainly contain injected agrin
at physiological concentrations.
Whatever the underlying mechanism, one can observe
a very similar partitioning of normal, denervated, remodel-
ing and newly formed NMJs in the patient muscle-biopsy
specimen and the rat muscle injected with mutant agrin.
Overall, the number of NMJ fragments is increased 3-fold
in mutated-agrin-treated muscle in comparison with
muscles injected with wild-type agrin or saline. However,
this fragmentation is accompanied by changes neither in
mean synaptic area nor in mean AChR synaptic density.
This implies that providing additional agrin, either
mutated or wild-type, to NMJs already containing endoge-
nous agrin could participate in the renewal of AChRs
within the 15 day period of the experiment in the same
manner as was shown with extrasynaptic clusters. Alterna-
tively, agrin injected in the junctional area could generate
AChR clusters near the NMJs, which could attract nerve
terminals because of their proximity.
A possible mechanism for inducing NMJ fragmentation
could involve the binding of agrin to molecules of the
basal lamina. The p.Gly1709Arg substitution is located in
the LG2 domain, which is involved in the binding of agrin
to a-dystroglycan15,20, and the interaction between agrin
and a-dystroglycan was shown to be involved in the struc-
turing of the basal lamina through laminin interaction
with the amino-terminal of agrin.34 However, a-dystrogly-
can was recently shown to be dispensable in restoration of
synaptogenesis12 and this argues against a role of a modi-
ﬁed interaction between a-dystroglycan andmutated agrin
in the NMJ changes. Anyhow, the binding experiments
showed that the mutation did not change the interaction
between agrin and a-dystroglycan.The AmerThe fragmentation of synaptic gutters could also be the
consequence of modiﬁcations of muscle cytoskeleton mol-
ecules, such as a-dystrobrevin35 or a-syntrophin.36 Mice
deﬁcient for these molecules have NMJs of frayed appear-
ance, similar to what was noted in the patient biopsy spec-
imen and the rat model.
Finally, for whatever reason, the axon terminals undergo
major modiﬁcations (diameter decrease and neuroﬁlament
destructuring, if not complete disappearance) in the pa-
tient and the injected rats. These alterations are likely to
induce neurotransmission dysfunction, which in turn
would induce the destabilization of the synaptic gutters.37
Consistently, agrin was shown to bind the a3Naþ/Kþ-
ATPase and to regulate its Naþ/Kþ-ATPase activity.38
a3Naþ/Kþ-ATPase was shown by axotomy to be located
in nerve terminals at the neuromuscular junction39 and
to modulate Naþ pump physiology.40 Mutations in agrin
could thereby interfere with neurotransmitter release and
so destabilize NMJs.
In conclusion, the p.Gly1709Arg substitution we have
identiﬁed does not seem to affect agrin’s canonical func-
tion, which is to induce the formation of the postsynaptic
compartment. Rather, it seems to perturb the maintenance
of the NMJ.41
Our results thus indicate that agrin possesses functions
in addition to those previously described to be mediated
by its N-terminal laminin-binding domain and C-terminal
A/z and B/z inserts. Further investigations will be needed to
pin down the detailed molecular mechanisms involved in
the destabilization of both the pre- and postsynaptic
compartments of the NMJ by this mutation.
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